Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Mar;15(3):287–293. doi: 10.1111/j.1365-2125.1983.tb01501.x

Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man.

G Taylor, J B Houston, J Shaffer, G Mawer
PMCID: PMC1427776  PMID: 6849764

Abstract

Blood concentrations of promethazine and promethazine sulphoxide have been measured following oral and intravenous administration of promethazine to seven healthy male volunteers. Promethazine disposition is characterised by a large volume of distribution (1970 1) and a high blood clearance (1.141 min-1). Less than 1% of the dose is excreted unchanged in the urine, therefore total body clearance is essentially metabolic clearance. In accord with this high clearance the oral availability of promethazine is only 25%. The absorption of promethazine from the gastrointestinal tract exceeds 80% in most subjects. Minimal metabolism by the gastrointestinal mucosa is implicated. Promethazine sulphoxide pharmacokinetics are consistent with a pronounced first pass effect. Although the area under the curve for this metabolite is not route dependent, there is a marked alteration in the shape of the metabolite curve when oral and intravenous data are compared. Evidence is presented to support the hypothesis that S-oxidation of promethazine is predominantly an hepatic event. The conclusions of previous investigators with regard to the role of the gut mucosa in S-oxidation of phenothiazines is critically assessed.

Full text

PDF
290

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alván G., Borga O., Lind M., Palmér L., Siwers B. First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma. Eur J Clin Pharmacol. 1977 Mar 11;11(3):219–224. doi: 10.1007/BF00606414. [DOI] [PubMed] [Google Scholar]
  2. Benet L. Z., Galeazzi R. L. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979 Aug;68(8):1071–1074. doi: 10.1002/jps.2600680845. [DOI] [PubMed] [Google Scholar]
  3. Cooper T. B. Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet. 1978 Jan-Feb;3(1):14–38. doi: 10.2165/00003088-197803010-00002. [DOI] [PubMed] [Google Scholar]
  4. Curry S. H., D'Mello A., Mould G. P. Destruction of chlorpromazine during absorption in the rat in vivo and in vitro. Br J Pharmacol. 1971 Jul;42(3):403–411. doi: 10.1111/j.1476-5381.1971.tb07125.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dahl S. G. Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther. 1976 Apr;19(4):435–442. doi: 10.1002/cpt1976194435. [DOI] [PubMed] [Google Scholar]
  6. Dahl S. G., Strandjord R. E. Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther. 1977 Apr;21(4):437–448. doi: 10.1002/cpt1977214437. [DOI] [PubMed] [Google Scholar]
  7. DiGregorio G. J., Ruch E. Human whole blood and parotid saliva concentrations of oral and intramuscular promethazine. J Pharm Sci. 1980 Dec;69(12):1457–1459. doi: 10.1002/jps.2600691234. [DOI] [PubMed] [Google Scholar]
  8. Eggert Hansen C., Rosted Christensen T., Elley J., Bolvig Hansen L., Kragh-Sorensen P., Larsen N. E., Naestoft J., Hvidberg E. F. Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol. 1976 Oct;3(5):915–923. doi: 10.1111/j.1365-2125.1976.tb00647.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gram L. F., Christiansen J. First-pass metabolism of imipramine in man. Clin Pharmacol Ther. 1975 May;17(5):555–563. doi: 10.1002/cpt1975175555. [DOI] [PubMed] [Google Scholar]
  10. Houston J. B. Drug metabolite kinetics. Pharmacol Ther. 1981;15(3):521–552. doi: 10.1016/0163-7258(81)90056-5. [DOI] [PubMed] [Google Scholar]
  11. Kriegelstein J., Lier F., Michaelis J. Albumin binding and hydrophobic character of promazine and chlorpromazine metabolites. Naunyn Schmiedebergs Arch Pharmacol. 1972;272(2):121–130. doi: 10.1007/BF00508763. [DOI] [PubMed] [Google Scholar]
  12. Lader M. Monitoring plasma concentrations of neuroleptics. Pharmakopsychiatr Neuropsychopharmakol. 1976 Jul;9(4):170–177. doi: 10.1055/s-0028-1094491. [DOI] [PubMed] [Google Scholar]
  13. Taylor G., Houston J. B. Simultaneous determination of promethazine and two of its circulating metabolites by high-performance liquid chromatography. J Chromatogr. 1982 Jun 11;230(1):194–198. doi: 10.1016/s0378-4347(00)81449-8. [DOI] [PubMed] [Google Scholar]
  14. Walle T., Conradi E. C., Walle U. K., Fagan T. C., Gaffney T. E. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther. 1980 Jan;27(1):22–31. doi: 10.1038/clpt.1980.4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES